STOCK TITAN

Pluri Inc. - PLUR STOCK NEWS

Welcome to our dedicated page for Pluri news (Ticker: PLUR), a resource for investors and traders seeking the latest updates and insights on Pluri stock.

Pluri Inc. (Nasdaq: PLUR, TASE: PLUR) is a leading biotechnology company that transforms cells into solutions to promote global wellbeing and sustainability. The company’s core business revolves around developing cell-based products for medical, agricultural, and industrial applications using its proprietary three-dimensional (3D) cell expansion technology. This innovative platform can grow cells in mass quantities with batch-to-batch consistency, making it suitable for applications ranging from regenerative medicine to food technology and beyond.

Pluri's flagship technology leverages placental expanded (PLX) cells that are derived from placental tissue. These cells release biomolecules such as cytokines, chemokines, and growth factors which aid in the healing of damaged tissues by stimulating the body’s natural regenerative mechanisms. The company operates a state-of-the-art manufacturing facility approved by the FDA, EMA, and PMDA, ensuring high standards and regulatory compliance.

In recent developments, Pluri has made significant strides in the agtech industry with the launch of its PluriAgtech business vertical and cell-based coffee product. The company secured a patent from the Israel Patent Office, further establishing its leadership in 3D cell expansion technology. Pluri’s cell-based coffee production method can significantly reduce water usage and farmland requirements, addressing the environmental challenges faced by traditional coffee farming.

Pluri is also advancing in the field of immune cell therapies. The company unveiled a novel method for expanding immune cells and obtained a U.S. patent for this technology, which mimics the natural environment of lymph nodes. This method ensures the integrity and functionality of immune cells, opening new possibilities for treatments of immune disorders and neurodegenerative diseases.

The company actively collaborates with various strategic partners to enhance its technological capabilities and explore new market opportunities. For instance, Pluri partnered with Wilk Technologies to develop cultured human and animal milk products for the elderly, aiming to address the growing demand for medical foods tailored to the nutritional needs of older adults.

Financially, Pluri is well-positioned with robust intellectual property, boasting over 140 active and granted patents. The company continues to expand its market presence, driven by a strong commitment to innovation and sustainability.

To stay updated on Pluri Inc.'s latest news and developments, visit the company’s official website at www.pluri-biotech.com or follow them on LinkedIn and X.

Rhea-AI Summary

Pluri (Nasdaq: PLUR) has announced a strategic partnership with Wilk Technologies to create a medical food product derived from human breast milk for the elderly. This innovative product utilizes Pluri's 3D cell-expansion technology in combination with Wilk's cell-cultured milk components. The global elderly nutrition market, valued at $25.2 billion, is projected to reach $39.7 billion within the next decade. This collaboration aims to meet the unique nutritional needs of seniors, enhancing their quality of life while addressing age-related health concerns and chronic illnesses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
none
-
Rhea-AI Summary

Pluri Inc. launched a novel immunotherapy platform for solid tumor cancer treatment utilizing placental MAIT cells, a unique type of immune cells with great potential. Pluri's proprietary technology overcomes challenges in expanding MAIT cells, offering advantages over conventional T cells. The global cancer immunotherapy market is projected to reach $275.11 billion by 2032. Renowned cancer researchers Dr. Prasad S. Adusumilli and Dr. Richard L. Kendall joined Pluri's Scientific Advisory Board to support this groundbreaking platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.03%
Tags
none
-
Rhea-AI Summary
Pluri Inc. unveils a groundbreaking method for expanding immune cells using proprietary technology, securing a new U.S. patent. The innovative 3D cell expansion technology mimics the natural lymph node environment, ensuring the integrity and functionality of immune cells. This advancement positions Pluri at the forefront of allogeneic cell therapy, promising significant therapeutic advancements and commercial success. The estimated total addressable market for immune cell engineering is projected to grow to $11.66 billion by 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
none
Rhea-AI Summary
Pluri Inc. announces participation in various conferences to showcase its innovative cell-based solutions and business verticals. The company's leadership will present at MIW, ATiO Conference 2024, Biomed Israel, and Bio International Convention, highlighting advancements in 3D cell expansion technology, cell-based coffee business, and PLX-PAD therapy product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.95%
Tags
conferences
-
Rhea-AI Summary
Pluri Inc. announces a reverse share split of its common shares at a ratio of 1-for-8, reducing outstanding shares from 41,816,959 to approximately 5,227,120. The split will not impact ownership or voting power, with fractional shares rounded up. Equiniti Trust Company, will act as the exchange agent for the reverse split.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.73%
Tags
-
Rhea-AI Summary
Pluri Inc. addresses price instability in the coffee industry highlighted in the International Coffee Organization's 2024 Market Report by introducing cell-based coffee production, offering a sustainable and innovative solution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.08%
Tags
none
Rhea-AI Summary
Pluri Inc. announces participation in key biotech conferences to showcase its innovative solutions for global wellbeing and sustainability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Pluri Inc. announces a manufacturing agreement between PluriCDMO™ and Remedy Cell Ltd for the production of the drug candidate RC-0315 to treat Idiopathic Pulmonary Fibrosis. The agreement aims to support Remedy Cell in manufacturing a clinical-grade Working Cell Bank and GMP batches for their Phase Ib clinical trial. Remedy Cell's CEO expresses excitement for the partnership, emphasizing the need for innovative treatments in complex conditions like IPF.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.08%
Tags
none
-
Rhea-AI Summary
Pluri Inc. announces the approval of a new patent titled “A System for 3D Cultivation of Plant Cells and Methods of Use” that revolutionizes the agricultural technology landscape. This patent enhances Pluri's 3D bioreactor technology, enabling efficient cultivation of plant cells for various applications, including the production of sustainable cell-based coffee. The technology reduces water usage by 98% and growing area by 95%, addressing environmental concerns. With the global cellular agriculture market projected to reach $515 billion by 2030, Pluri's patented technology places it at the forefront of innovation in the agtech industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.96%
Tags
none
Rhea-AI Summary
Pluri Inc. appoints attorney James Roosevelt, Jr. to its Advisory Board, bringing expertise in public policy, health, and business matters. Mr. Roosevelt's background in healthcare leadership and advocacy will aid Pluri in advancing its mission of developing sustainable cell-based treatments for unmet medical needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.64%
Tags
management

FAQ

What is the current stock price of Pluri (PLUR)?

The current stock price of Pluri (PLUR) is $4.82 as of December 20, 2024.

What is the market cap of Pluri (PLUR)?

The market cap of Pluri (PLUR) is approximately 25.3M.

What is Pluri Inc. known for?

Pluri Inc. is known for its proprietary 3D cell expansion technology used to develop cell-based products for medical, agricultural, and industrial applications.

What are PLX cells?

PLX cells are placental-derived, mesenchymal-like stromal cells developed by Pluri Inc. that release biomolecules to aid in tissue healing and regeneration.

What recent achievements has Pluri Inc. made?

Pluri Inc. recently secured a patent for its 3D cell expansion technology, launched a cell-based coffee product, and developed a novel method for expanding immune cells.

How does Pluri’s cell-based coffee benefit the environment?

Pluri’s cell-based coffee production method uses 98% less water and 95% less farmland compared to traditional methods, addressing environmental challenges in coffee farming.

What partnerships has Pluri Inc. entered into recently?

Pluri partnered with Wilk Technologies to develop cultured human and animal milk products aimed at improving nutrition for the elderly.

What is Pluri's approach to immune cell therapies?

Pluri has developed a patented method for expanding immune cells in a 3D environment, mimicking the natural lymph node conditions to ensure cell integrity and functionality.

What markets does Pluri Inc. operate in?

Pluri operates in regenerative medicine, food-tech, and agtech. The company aims to expand its 3D cell-based technology to additional industries requiring mass cell production.

How many patents does Pluri Inc. hold?

Pluri Inc. holds over 140 active and granted patents, strengthening its competitive position in the biotechnology sector.

Where can I find more information about Pluri Inc.?

You can find more information about Pluri Inc. on their official website at www.pluri-biotech.com and by following them on LinkedIn and X.

What is PLX-R18?

PLX-R18 is a cell therapy product developed by Pluri for treating hematopoietic complications of acute radiation syndrome (H-ARS) and has shown promising results in clinical trials.

Pluri Inc.

Nasdaq:PLUR

PLUR Rankings

PLUR Stock Data

25.29M
4.27M
23.52%
9.65%
0.16%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
HAIFA